Akums Drugs and Pharmaceuticals (AKUMS) Stock Overview
Manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for AKUMS from our risk checks.
AKUMS Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Akums Drugs and Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹545.35 |
| 52 Week High | ₹597.00 |
| 52 Week Low | ₹409.30 |
| Beta | 0 |
| 1 Month Change | -2.11% |
| 3 Month Change | 8.94% |
| 1 Year Change | -4.04% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -31.51% |
Recent News & Updates
There May Be Reason For Hope In Akums Drugs and Pharmaceuticals' (NSE:AKUMS) Disappointing Earnings
The market for Akums Drugs and Pharmaceuticals Limited's ( NSE:AKUMS ) shares didn't move much after it posted weak...Akums Drugs and Pharmaceuticals Limited Just Beat Revenue Estimates By 9.0%
Investors in Akums Drugs and Pharmaceuticals Limited ( NSE:AKUMS ) had a good week, as its shares rose 4.5% to close at...Recent updates
There May Be Reason For Hope In Akums Drugs and Pharmaceuticals' (NSE:AKUMS) Disappointing Earnings
The market for Akums Drugs and Pharmaceuticals Limited's ( NSE:AKUMS ) shares didn't move much after it posted weak...Akums Drugs and Pharmaceuticals Limited Just Beat Revenue Estimates By 9.0%
Investors in Akums Drugs and Pharmaceuticals Limited ( NSE:AKUMS ) had a good week, as its shares rose 4.5% to close at...
AKUMS: Zambia Manufacturing Buildout Will Support Future Earnings Expansion
Analysts have kept their fair value estimate for Akums Drugs and Pharmaceuticals unchanged at ₹646.67, citing only modest tweaks to inputs such as a slightly lower discount rate and a marginally softer future P/E assumption, rather than any shift in the underlying company outlook. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).AKUMS: Zambia Expansion And Senior Leadership Moves Will Support Earnings
Analysts have kept their fair value estimate for Akums Drugs and Pharmaceuticals steady at ₹646.67, with only marginal adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions. This reflects fine tuning of their models rather than a change in overall view.AKUMS: Zambia Manufacturing Buildout Will Support Future Margins And Earnings
Analysts have lifted their price target on Akums Drugs and Pharmaceuticals to ₹646.67 from ₹638.33, citing updated assumptions around revenue growth, profit margins, and a slightly different forward P/E framework. What's in the News The Board approved an investment of US$24 million (about ₹2,000 million) in Akums Healthcare (Zambia) Private Limited, a recently incorporated subsidiary in Zambia, to be infused through equity and or debt secured by MIGA insurance (Board meeting filing).AKUMS: Zambian Manufacturing Expansion Will Support Future Earnings And Margin Strength
Analysts have modestly revised their price target for Akums Drugs and Pharmaceuticals to ₹638.33 per share, reflecting slightly lower discount rate and future P/E assumptions while maintaining their outlook on revenue growth and profit margins. What's in the News The board has approved a USD 24 million (about INR 2,000 million) investment in subsidiary Akums Healthcare Zambia to establish a manufacturing facility and expand its presence in Zambia and neighboring African markets, with funding via equity and/or debt secured by MIGA insurance (Key Developments).AKUMS: Zambian Expansion Will Drive Earnings Momentum And Future Market Reach
Analysts have maintained their price target for Akums Drugs and Pharmaceuticals at ₹638.33, noting only minimal adjustments to underlying assumptions such as the discount rate and future earnings expectations. What's in the News The board of Akums Drugs and Pharmaceuticals approved an investment of USD 24 million (INR 2000 million approx.) in its Zambian subsidiary to establish a manufacturing facility and expand business in African markets (Board Meeting, Nov 13, 2025).AKUMS: Investment in Zambia Subsidiary Will Drive Stronger Earnings Momentum
Analysts have revised their price target for Akums Drugs and Pharmaceuticals downward from ₹691.67 to ₹638.33, citing updated assessments of growth prospects and market conditions. What's in the News A board meeting is scheduled for November 13, 2025, at 14:30 IST to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Major Pharma Contract And Global Expansion Will Forge Future Promise
Long-term export contract, product diversification, and international expansion are driving predictable revenue growth, profitability, and geographic risk mitigation.Concerns Surrounding Akums Drugs and Pharmaceuticals' (NSE:AKUMS) Performance
Akums Drugs and Pharmaceuticals Limited ( NSE:AKUMS ) just released a solid earnings report, and the stock displayed...Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS) Not Flying Under The Radar
Akums Drugs and Pharmaceuticals Limited's ( NSE:AKUMS ) price-to-earnings (or "P/E") ratio of 57.6x might make it look...Shareholder Returns
| AKUMS | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 3.9% | -0.5% | -0.8% |
| 1Y | -4.0% | -0.6% | -2.9% |
Return vs Industry: AKUMS underperformed the Indian Life Sciences industry which returned -0.6% over the past year.
Return vs Market: AKUMS underperformed the Indian Market which returned -2.9% over the past year.
Price Volatility
| AKUMS volatility | |
|---|---|
| AKUMS Average Weekly Movement | 5.5% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.8% |
Stable Share Price: AKUMS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: AKUMS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 7,536 | Sanjeev Jain | www.akums.in |
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, capsules, injectables, opthalmics, and soft gelatin capsules for therapeutic areas, such as gynaecology, cardiology, orthopaedics, pediatrics, and dermatology, as well as anti-infectives, pain management and gastroenterology.
Akums Drugs and Pharmaceuticals Limited Fundamentals Summary
| AKUMS fundamental statistics | |
|---|---|
| Market cap | ₹83.49b |
| Earnings (TTM) | ₹2.55b |
| Revenue (TTM) | ₹43.59b |
Is AKUMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKUMS income statement (TTM) | |
|---|---|
| Revenue | ₹43.59b |
| Cost of Revenue | ₹25.14b |
| Gross Profit | ₹18.45b |
| Other Expenses | ₹15.90b |
| Earnings | ₹2.55b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.67 |
| Gross Margin | 42.34% |
| Net Profit Margin | 5.85% |
| Debt/Equity Ratio | 2.2% |
How did AKUMS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/08 03:15 |
| End of Day Share Price | 2026/06/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akums Drugs and Pharmaceuticals Limited is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashwin Mehta | Ambit Capital |
| Pranav Chawla | Ambit Capital |
| Gaurav Tinani | Ambit Capital |